TELISOTUZUMAB ADIZUTECAN
UNII CVX52RV2DC

Substance Identification & Data

This profile provides standardized clinical and technical data for Telisotuzumab Adizutecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CVX52RV2DC.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2850366-99-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

CVX52RV2DC

CAS Registry Number

2850366-99-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TELISOTUZUMAB ADIZUTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C184368

National Cancer Institute reference terminology for clinical and research data.

INN ID

13001

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Telisotuzumab Adizutecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Telisotuzumab Adizutecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Telisotuzumab Adizutecan

Common Names & Synonyms

Immunoglobulin G1, anti-(human hepatocyte growth factor receptor) (human-Mus musculus monoclonal ABT-700 heavy chain), disulfide with human-Mus musculus monoclonal ABT-700 κ-chain, dimer, reduced, hexakis(thioether) with N-(2-mercaptoacetyl)-L-valyl-N-[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]bicyclo[1.1.1]pent-1-yl]-L-alaninamide

Telisotuzumab adizutecan [WHO-DD]

immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody, conjugated on an average of 6 cysteinyl residues to adizutecan, comprising a linker and a camptothecin derivative; H-gamma1 heavy chain humanized (1-445) [VH (Homo sapiens IGHV1-2*02 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14 (CH1 R120 (215) (119-216), hinge 1-15 K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (119-445)], (221-218')-disulfide with L-kappa light chain humanized (1'-218') [V-KAPPA (Homo sapiens IGKV4-1*01 (85.1%) -IGKJ4*01 (100%), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157'), V101 (195') (112'-218')]; dimer (223-223''-225-225'':228-228'')-trisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1SV, expressing the enzyme glutamine synthetase (GS), glycoform alfa; substituted at the sulfur atoms of an average of 6 L-cysteinyl residues among 221, 223, 225, 228, 218', 221'', 223'', 225'', 228'' and 218''' with radical group 2-{[(2S)-1-{[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy-14-methyl-8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-14-yl]bicyclo[1.1.1]pentan-1-yl}amino)-1-oxopropan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-2-oxoethyl (adizutecan)

External Clinical & Regulatory Resources

Previous UNIICVX06U60Y8

Next UNIICVX8DX8KWA